Bristol Myers Squibb Company BMY
62.86
1.36
2.21%
as of 25 Sep
- Market cap
- $125.9B
- P/E
- 13.8×
Follow BMY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bristol Myers Squibb Company (BMY) P/S ratio
As of 25 September 2026, Bristol Myers Squibb Company (BMY) trades at a P/S ratio of 2.6×. Over the past ten years it has ranged from 1.7× (July 2024) to 7.3× (June 2016); the current reading is higher than 24% of that period. That is below the Drug Manufacturers General industry median of 3.3× and below the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.3× | (4.09%) |
| FY2024 | 2.4× | (2.14%) |
| FY2023 | 2.4× | (27.26%) |
| FY2022 | 3.3× | 11.69% |
| FY2021 | 3.0× | (9.37%) |
| FY2020 | 3.3× | (21.30%) |
| FY2019 | 4.2× | 11.26% |
| FY2018 | 3.8× | (22.50%) |
| FY2017 | 4.9× | (5.07%) |
| FY2016 | 5.1× | (26.15%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 2.4× | (6.17%) |
| Mar 2026 | 2.5× | 11.99% |
| Dec 2025 | 2.3× | 19.09% |
| Sep 2025 | 1.9× | (3.20%) |
| 42 more quarters | Free account |
Against its own ten years
Low 1.7×
High 7.3×
Ten-year median
3.4×
Current reading's percentile
24
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| SNY Sanofi compare | 1.7× |
| GSK GSK PLC Sponsored ADR compare | 2.2× |
| PFE Pfizer Inc. compare | 2.6× |
| BMY Bristol Myers Squibb Company | 2.6× |
| NVO Novo Nordisk A/S compare | 3.3× |
| AZN AstraZeneca PLC compare | 4.2× |
| NVS Novartis AG compare | 4.9× |
| AMGN Amgen Inc. compare | 5.9× |
| GILD Gilead Sciences, Inc. compare | 6.2× |
| Drug Manufacturers General industry median | 3.3× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on BMY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement